| Gene Symbol | CLDN5 |
| Full Name | Claudin-5 |
| Chromosome | 22q11.21 |
| Protein Type | Structural Protein |
| Target Class | Structural Protein |
| Function | Tight junction protein modulation - no established druggable mechanisms |
| Mechanism of Action | Tight junction protein modulation - no established druggable mechanisms |
| Primary Expression | Brain endothelial cells, Tight junctions of blood-brain barrier |
| Druggability | Undruggable (0.20) |
| Clinical Stage | Approved |
| Amino Acids | 218 aa |
| Exons | 4 |
| Pathways | Cerebrovascular |
| UniProt ID | O00511 |
| NCBI Gene ID | 9079 |
| Ensembl ID | ENSG00000184113 |
| OMIM | 602507 |
| GeneCards | CLDN5 |
| Human Protein Atlas | CLDN5 |
| Associated Diseases | ALS, Brain Edema, Stroke, blood-retinal barrier integrity, neurodegeneration |
| Known Drugs/Compounds | curcumin, resveratrol |
| Interactions | OCLN, CAV1, HIF1A, IL23A, BECN1, IL6 |
| SciDEX Target | View Target Profile (5 clinical trials) |
| SciDEX Hypotheses | Vascular-Glial Interface Restoration |
| KG Connections | 381 knowledge graph edges |
| Databases | GeneCardsHPASTRING |